CXCR2 and hepatocellular carcinoma: C-X-C chemokine receptor type 2 (CXCR2) antagonist AZD5069 overcame immunotherapy secondary resistance in hepatocellular carcinoma by targeting myeloid interleukin-8/CXCR2 signaling (41).